RE:RE:RE:RE:RE:RE:RE:RE:Survey SaysThe first sentence of your post is at least two years away. It's already been close to two years and they haven't found the 7th patient. It sounds like there is a lineup forming at the exit. Any news will be sold into and the stock will go nowhere.
Redbaron2211 wrote: Once we have a patient implanted with a higher capacity cell pouch and insulin independence is achieved without top up I would expect to see a deal. Until then it's possible but not a high probability in my opinion. Maybe big pharma has enough confidence to pay up based on the data we have or some smaller deal but all we can really expect near term is a TSX uplist with hopefully clinical updates and maybe something on the other indications.
Sernova has actually outperformed most indices by quite a bit in the last year just staying more or less flat and didnt take a 60-90% haircut like a lot of the growth which does give validation at least from the markets prespective to the device. Hopefully that resilience is indicative of something coming near term but apart from the tax implications it doesn't hurt diversifying some into something like commodities and PM's. Maybe selling some will kick in murphys law and we will finally see a deal.